Ocular Therapeutix (OCUL) Price Target Raised to $50 at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Ocular Therapeutix (OCUL) Target Raised to $49 at Oppenheimer; Positive Data Validates Platform
March 11, 2015 7:38 AM EDTOppenheimer analyst Yigal Nochomovitz reiterated an Outperform-rated and boosted his price target on Ocular Therapeutix (NASDAQ: OCUL) to $49.00 (from $42.00) saying positive Phase 3a data validates its technology platform.
commenetd, "Ocular reported positive OTX-DP Phase 3a top-line data in post-surgical pain/inflammation as expected. Both... More
Ocular Therapeutix (OCUL) Tops Q4 EPS by 1c
March 10, 2015 6:46 AM EDTOcular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.37), $0.01 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $505 thousand versus the consensus estimate of $200 thousand.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
... MoreOcular Therapeutix (OCUL) Announces OTX-DP Met Primary Endpoints in First Phase 3
March 10, 2015 6:33 AM EDTOcular Therapeutix (NASDAQ: OCUL) announced positive topline data from the first of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP (Sustained Release Dexamethasone), for the treatment of ocular inflammation and pain following cataract surgery. The Phase 3a study, which enrolled 247 patients, met both primary efficacy measures, achieving a statistically significant improvement in the reduction of inflammatory cells and pain. 33.7% of OTX-DP-treated patients showed an absence of inflammatory cells in the anterior chamber of the study eye on day 14 following drug product insertion, compared to 14.6% of those receiving placebo... More
